Literature DB >> 32396168

Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.

Andrew M Borman1,2, Jessica M Hughes3,2, Debra Oliver1, Mark Fraser1, Julie Sunderland3,2, Alan R Noel3,2, Elizabeth M Johnson1,2.   

Abstract

We determined isavuconazole serum concentrations for 150 UK patients receiving standard isavuconazole dosing regimens, including serial therapeutic drug monitoring for several patients on prolonged therapy. Mean trough isavuconazole concentrations in these patients were virtually identical to those reported previously from clinical trials, although greater variability was seen in patients below 18 years of age. Serial monitoring in patients receiving prolonged therapy suggested gradual, near-linear accumulation of the drug over many weeks. © Crown copyright 2020.

Entities:  

Keywords:  Isavuconazole; LC-MS/MS; accumulation; drug concentrations; therapeutic drug monitoring

Mesh：

Substances：

Year:  2020        PMID： 32396168     DOI： 10.1093/mmy/myaa022

Source DB:  PubMed          Journal:  Med Mycol        ISSN： 1369-3786            Impact factor:   4.076


  9 in total

Review 1.  New Perspectives on Antimicrobial Agents: Isavuconazole.

Authors:  James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2022-08-15       Impact factor: 5.938

2.  Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole.

Authors:  Malene Risum; Mai-Britt Vestergaard; Ulla Møller Weinreich; Marie Helleberg; Nadja Hawwa Vissing; René Jørgensen
Journal:  Antibiotics (Basel)       Date:  2021-04-23

3.  Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement.

Authors:  R P Miller; L Farrugia; J Leask; K Khalsa; N Khanna; L Melia
Journal:  Med Mycol Case Rep       Date:  2021-03-17

4.  In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.

Authors:  Andrew M Borman; Mark Fraser; Zoe Patterson; Michael D Palmer; Elizabeth M Johnson
Journal:  J Fungi (Basel)       Date:  2021-04-02

5.  Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.

Authors:  Michelle Miller; Geena Kludjian; Kerry Mohrien; Kazumi Morita
Journal:  Am J Health Syst Pharm       Date:  2022-07-22       Impact factor: 2.980

6.  Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.

Authors:  Dennis J Woerde; Luke A Wittenburg; Jonathan D Dear
Journal:  J Vet Intern Med       Date:  2022-05-26       Impact factor: 3.175

Review 7.  Isavuconazole for COVID-19-Associated Invasive Mold Infections.

Authors:  Nadir Ullah; Chiara Sepulcri; Malgorzata Mikulska
Journal:  J Fungi (Basel)       Date:  2022-06-28

8.  Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring.

Authors:  Léa Bolcato; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque; Elodie Gautier-Veyret
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

9.  Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?

Authors:  Pier Giorgio Cojutti; Alessia Carnelutti; Davide Lazzarotto; Emanuela Sozio; Anna Candoni; Renato Fanin; Carlo Tascini; Federico Pea
Journal:  Pharmaceutics       Date:  2021-12-06       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.